Development and testing of an ex vivo, live tumor fragment platform for the prediction of immune checkpoint inhibitor response and relationship to approved biomarkers

This poster presents the latest data on the elive™ platform using routine core needle and forceps biopsies across multiple tumor types and clinical sites. Using live tumor fragments, we developed the elive index, a binary cytokine-based classifier of ex vivo ICI response. In a validation cohort, the elive index correctly predicted clinical benefit in 93% of patients and identified platform responders among patients negative for approved ICI biomarkers. In the video below, Hinco Gierman, PhD, walks you through the poster presented at ASCO 2026.